The FDA approved a controversial, $56,000-a-year Alzheimer's drug despite opposition inside the agency, internal memos show
Published
The director of the FDA's biostatistics office said there wasn't enough evidence to approve Aduhelm, the first new Alzheimer's treatment in decades.
Full Article